<?xml version="1.0" encoding="UTF-8"?>
<p>Of 274 dogs with proven or suspected upper or lower respiratory tract infections, 171 (62%) were treated with antimicrobials of the following classes: potentiated aminopenicillins (68.4%), fluoroquinolones (15.8%), non‐potentiated (NP) aminopenicillins (20.4%), tetracyclines (22.2%), first‐generation cephalosporins (2%), third‐generation cephalosporins, lincosamides, macrolides and nitroimidazoles (0.8% each). In 48.2% (132/274), therapeutic decisions regarding antimicrobial therapy were judged appropriate (JS‐1), in 23.3% (64/274) inappropriate (JS‐2 n = 4; JS‐3 n = 26).</p>
